ARTICLE | Company News
BioCritica, Eli Lilly deal
May 30, 2011 7:00 AM UTC
Eli Lilly formed newco BioCritica with investors Care Capital and NovaQuest. BioCritica will have exclusive rights in the U.S. to develop and commercialize Lilly's sepsis drug Xigris drotrecogin alfa ...